Cochrane · systematic review · CD010908
Cyclophosphamide for connective tissue disease–associated interstitial lung disease
Barnes, H, Holland, AE, Westall, GP, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
AirwaysAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
14
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 13 · 92.9%Moderate 1 · 7.1%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Cyclophosphamide compared with placebo for connective tissue disease–associated interstitial lung disease
Population: people with connective tissue disease‐associated interstitial lung disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in lung function (FVC % predicted) Cyclophosphamide vs placebo | no estimate extracted | 2 studies · 182 participants | Low |
Change in lung function (diffusing capacity of the lung for carbon monoxide (DLCO) % predicted) Cyclophosphamide vs placebo | no estimate extracted | 2 studies · 182 participants | Low |
Adverse events: pneumonia 12‐month Cyclophosphamide vs placebo | OR 1.7 [0.55, 5.32] | 2 studies · 203 participants | Low |
Adverse events: haematuria 12‐month Cyclophosphamide vs placebo | OR 2.6 [1.12, 6.03] | 2 studies · 203 participants | Low |
Health‐related quality of life (HAQ‐DI) Cyclophosphamide vs placebo | no estimate extracted | 1 study · 158 participants | Moderate |
All‐cause mortality 12‐month Cyclophosphamide vs placebo | OR 0.94 [0.19, 4.77] | 2 studies · 179 participants | Low |
Cyclophosphamide compared with mycophenolate for connective tissue disease–associated interstitial lung disease
Population: people with connective tissue disease‐associated interstitial lung disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in lung function (FVC % predicted) Cyclophosphamide vs mycophenolate | no estimate extracted | 2 studies · 149 participants | Low |
Change in lung function (diffusing capacity of the lung for carbon monoxide (DLCO) % predicted) Cyclophosphamide vs mycophenolate | no estimate extracted | 2 studies · 145 participants | Low |
Adverse events: leukopenia 12‐month Cyclophosphamide vs mycophenolate | OR 6.86 [3.23, 14.58] | 2 studies · 300 participants | Low |
Adverse events: pneumonia 12‐month Cyclophosphamide vs mycophenolate | OR 1.01 [0.48, 2.14] | 2 studies · 300 participants | Low |
Adverse events: anaemia 12‐month Cyclophosphamide vs mycophenolate | OR 1.63 [0.65, 4.11] | 2 studies · 300 participants | Low |
Adverse events: thrombocytopenia 12‐month Cyclophosphamide vs mycophenolate | RD 0.03 [0, 0.06] | 2 studies · 300 participants | Low |
Health‐related quality of life (HAQ‐DI) Cyclophosphamide vs mycophenolate | no estimate extracted | 1 study · 142 participants | Low |
All‐cause mortality 12‐month Cyclophosphamide vs mycophenolate | OR 1.6 [0.65, 3.95] | 2 studies · 187 participants | Low |